Pacira BioSciences, Inc. (PCRX) support and resistance · P/E 174, rev $369.8M
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page maps Pacira BioSciences, Inc. (PCRX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new PCRX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the PCRX quote page for the session range and the stock page for the full model.
Not investment advice.